Skip to main content
. Author manuscript; available in PMC: 2011 Jan 1.
Published in final edited form as: Clin Cancer Res. 2010 Jan 1;16(1):154–163. doi: 10.1158/1078-0432.CCR-09-2850

Figure 4. Radiation therapy and temozolomide are more efficient on GBM tumor-initiating cells when used in combination with imetelstat.

Figure 4

A. Cell survival assay (MTT) performed on cells treated with the telomerase inhibitor drug (16 weeks), TMZ and irradiation (5Gy). The data was normalized to the control, oligonucleotide mismatch-treated cells; B. Addition of TMZ to tumor cells pretreated with imetelstat for 72 hours produced a marked impact on tumor cell viability (P<0.001), as indicated by the MTT assay. Treatment with TMZ alone or in combination with 5Gy irradiation produced only a small decrease in tumor cell proliferation. C. Western blot of GBM tumor-initiating cells pre-treated with imetelstat (72hrs) followed by IR (5Gy) indicated a effect on DNA double strand breaks as measured by increased γH2AX (Ser139) and 53BP1 phosphorylation; D. Western blot of GBM tumor-initiating cells treated with a combination of imetelstat and TMZ (5, 10 and 20μM) showed increased activation of γH2AX and 53BP1 phosphorylation compared to the mismatch controls.